Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Larimar Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: Larimar issued a press release on September 29, 2025, announcing data from an ongoing long-term open-label study evaluating daily subcutaneous injections of Nomlabofusp in participants with Friedreich's Ataxia. Although Larimar characterized the data as "positive", the press release disclosed that anaphylaxis or a severe allergic reaction was reported in seven participants. Following this news, Larimar's stock price fell over 33% on September 29, 2025.
In order to be eligible to join the LRMR class action lawsuit, you must have incurred a loss on shares of Larimar Therapeutics, Inc. purchased during the class period listed above.
TOP
